Joseph Thome
Stock Analyst at TD Cowen
(2.19)
# 1,478
Out of 4,667 analysts
23
Total ratings
50%
Success rate
-3.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNS Marinus Pharmaceuticals | Downgrades: Hold | n/a | $0.31 | - | 2 | Oct 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $364.33 | +9.79% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $22.19 | - | 1 | Jul 2, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Hold | n/a | $2.66 | - | 2 | Jun 18, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $27.91 | +21.82% | 1 | Jun 17, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $80 → $90 | $85.64 | +5.09% | 2 | Apr 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $2.99 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi | Initiates: Outperform | n/a | $1.65 | - | 1 | Mar 5, 2024 | |
| PTCT PTC Therapeutics | Maintains: Market Perform | $32 → $30 | $41.96 | -28.50% | 2 | Mar 1, 2024 | |
| YMAB Y-mAbs Therapeutics | Downgrades: Market Perform | n/a | $10.54 | - | 1 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $39.34 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.50 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.62 | - | 1 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $94.60 | +37.42% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.12 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $17.93 | - | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.94 | - | 1 | Jul 15, 2021 |
Marinus Pharmaceuticals
Oct 25, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.31
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $364.33
Upside: +9.79%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $22.19
Upside: -
Aerovate Therapeutics
Jun 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.66
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $27.91
Upside: +21.82%
Intra-Cellular Therapies
Apr 17, 2024
Maintains: Buy
Price Target: $80 → $90
Current: $85.64
Upside: +5.09%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $2.99
Upside: -
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.65
Upside: -
PTC Therapeutics
Mar 1, 2024
Maintains: Market Perform
Price Target: $32 → $30
Current: $41.96
Upside: -28.50%
Y-mAbs Therapeutics
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $10.54
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $39.34
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $6.50
Upside: -
Oct 10, 2022
Initiates: Outperform
Price Target: n/a
Current: $11.62
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $94.60
Upside: +37.42%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $13.12
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $17.93
Upside: -
Jul 15, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.94
Upside: -